Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
“We need all the capital we can get our hands on," the company states.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
